Compare VAL & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAL | ORKA |
|---|---|---|
| Founded | 1975 | 2004 |
| Country | Bermuda | United States |
| Employees | 5070 | 68 |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.4B |
| IPO Year | N/A | N/A |
| Metric | VAL | ORKA |
|---|---|---|
| Price | $75.40 | $87.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $64.00 | ★ $92.50 |
| AVG Volume (30 Days) | 846.9K | ★ 1.3M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.76 | N/A |
| P/E Ratio | $16.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.23 | $10.97 |
| 52 Week High | $114.12 | $91.00 |
| Indicator | VAL | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 30.68 | 73.57 |
| Support Level | $47.57 | $27.81 |
| Resistance Level | $104.05 | $91.00 |
| Average True Range (ATR) | 3.04 | 4.74 |
| MACD | -1.03 | 2.27 |
| Stochastic Oscillator | 6.09 | 93.72 |
Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.